Nedosiran (sodium)

Nedosiran (DCR-PHXC) sodium is an RNA interference (RNAi) targeting lactate dehydrogenase (LDH) . Nedosiran sodium represents an impactful potential therapeutic for primary hyperoxaluria (PH) with end-stage renal disease (ESRD) . Nedosiran sodium is a GalNAc-dsRNA conjugate[1][2][3].

Product Specifications

CAS Number

[2247026-22-6]

Product Name Alternative

DCR-PHXC (sodium)

UNSPSC

12352208

Target

Lactate Dehydrogenase; Small Interfering RNA (siRNA)

Type

Oligonucleotides

Related Pathways

Epigenetics; Metabolic Enzyme/Protease

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/nedosiran-sodium.html

Purity

92.35

Solubility

H2O : 100 mg/mL (ultrasonic)

Smiles

[Nedosiran(sodium)]

Molecular Formula

C662H865F19N231O413P57S6.xNa

Molecular Weight

20985 (free acid)

References & Citations

[1]Kevin Shee, et al. Nedosiran Dramatically Reduces Serum Oxalate in Dialysis-Dependent Primary Hyperoxaluria 1: A Compassionate Use Case Report. Urology.2021 Oct;156:e147-e149.|[2]Gema Ariceta, et al. Hepatic Lactate Dehydrogenase A: An RNA Interference Target for the Treatment of All Known Types of Primary Hyperoxaluria. Kidney Int Rep. 2021 Feb 3;6 (4) :1088-1098.|[3]Thomas A Forbes, et al. Therapeutic RNA interference: A novel approach to the treatment of primary hyperoxaluria. Br J Clin Pharmacol. 2021 May 22.